[Skip to Content]
[Skip to Content Landing]
June 1981

Efficacy of an Oral Angiotensin-Converting Enzyme Inhibitor (Captopril) in Severe Hypertension

Author Affiliations

From the Division of Hypertension, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor. Dr Nicholls is now with The Medical Unit, Princess Margaret Hospital, Christchurch, New Zealand.

Arch Intern Med. 1981;141(7):907-910. doi:10.1001/archinte.1981.00340070087018

• The antihypertensive effect of captopril was assessed during short- and long-term periods in ten patients with elevated blood pressure readings that were uncontrollable by standard therapy (supine diastolic blood pressure of >100 mm Hg, with a regimen of propranolol hydrochloride, hydralazine hydrochloride, and hydrochlorothiazide). When given alone, captopril therapy was unable to normalize the blood pressure in any patient. The addition of hydrochlorothiazide to the captopril therapy normalized the blood pressure in one patient and sharply improved the blood pressure in four others. The blood pressure in the remaining patients responded inadequately to this combination. The addition of propranolol to captopril and hydrochlorothiazide reduced the blood pressure further in most cases (seven of the ten patients had normal blood pressure readings while they received these three drugs). In four patients, the blood pressure response to the added propranolol was unrelated to changes in plasma angiotensin II concentration. Captopril was helpful in the management of refractory hypertension in most cases.

(Arch Intern Med 1981;141:907-910)